November 18, 2026
Health news, explained with evidence
LIVE

New Report Confirms Safety of Early MMR Vaccination as US Loses Measles Elimination Status

🧠 AI Analysis 2 min read 👁 3

Amid a growing national measles resurgence, a University of Minnesota report indicates that giving the MMR vaccine to infants aged 6 to 11 months is safe and provides meaningful protection.

New Report Confirms Safety of Early MMR Vaccination as US Loses Measles Elimination Status🧠AI Analysis

Photo: Medical Xpress

Key points

  • Infants aged 6 to 11 months can safely receive an early MMR zero dose.
  • The US recently lost its 26-year measles elimination status after recording over 5,400 cases.
  • Data show vaccine effectiveness is 58% before 9 months and 83% from 9 to 11 months.

A recent evaluation from the Center for Infectious Disease Research and Policy Vaccine Integrity Project indicates that infants between 6 and 11 months old can safely receive the measles, mumps, and rubella vaccine. This early immunization, often termed a zero dose, is highlighted as an important option for babies facing potential exposure during holiday travel or in regions experiencing active viral spread.

Measles Resurgence and Loss of Status

The United States has documented over 5,400 measles cases and 10 deaths across 45 states this year. Consequently, the Pan American Health Organization officially removed the nation's measles elimination status, which had been maintained for more than 26 years. This revocation indicates continuous viral transmission within the country for at least a full year, compounding risks as maternal antibodies fade during an infant's early months.

Evidence on Vaccine Safety and Effectiveness

Data reviewed by the project demonstrate that the early dose confers substantial protection without elevating safety concerns relative to standard timelines. Vaccine effectiveness reaches 58% when administered before 9 months and 83% between 9 and 11 months. Clinical trials and safety reviews involving thousands of infants found no elevated risk of adverse events in younger cohorts compared to routine vaccination groups, though experts emphasize that early recipients must still complete the standard two-dose series starting at 12 to 15 months for long-term immunity.

Overall, the MMR vaccine is safe and highly effective at preventing severe disease and complications from the measles virus.

What to know: While the vaccine can occasionally induce a fever and a very low risk of associated febrile seizures, experts confirm this risk does not increase in younger infants. Amid reduced federal communication regarding the outbreak, parents and caregivers should consult healthcare providers to evaluate individual travel risks and personal medical decisions.

Source Medical Xpress — medicalxpress.com/news/2026-11-measles-cases-mount-highlights-safety.ht… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.